1. Home
  2. WLFC vs PHAR Comparison

WLFC vs PHAR Comparison

Compare WLFC & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Willis Lease Finance Corporation

WLFC

Willis Lease Finance Corporation

HOLD

Current Price

$191.35

Market Cap

1.2B

ML Signal

HOLD

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$17.08

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WLFC
PHAR
Founded
1985
1988
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.1B
IPO Year
1997
2020

Fundamental Metrics

Financial Performance
Metric
WLFC
PHAR
Price
$191.35
$17.08
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$160.00
$39.00
AVG Volume (30 Days)
45.4K
18.0K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
0.88%
N/A
EPS Growth
146.23
N/A
EPS
13.89
N/A
Revenue
$569,223,000.00
N/A
Revenue This Year
$2.75
$10.04
Revenue Next Year
$7.35
$2.51
P/E Ratio
$13.02
$3,041.22
Revenue Growth
36.00
N/A
52 Week Low
$114.01
$7.79
52 Week High
$207.05
$21.34

Technical Indicators

Market Signals
Indicator
WLFC
PHAR
Relative Strength Index (RSI) 64.10 55.68
Support Level $192.00 $16.55
Resistance Level $206.77 $17.60
Average True Range (ATR) 7.05 0.64
MACD 2.51 0.13
Stochastic Oscillator 97.18 76.15

Price Performance

Historical Comparison
WLFC
PHAR

About WLFC Willis Lease Finance Corporation

Willis Lease Finance Corp, with its subsidiaries, is a lessor and servicer of commercial aircraft and aircraft engines. The company has two reportable business segments, which include Leasing and Related Operations and Spare Parts Sales. A majority of its revenue is generated from the Leasing and Related Operations segment, which involves acquiring and leasing, under operating leases, commercial aircraft, aircraft engines, and other aircraft equipment and the selective purchase and resale of commercial aircraft engines, aircraft equipment, and other related businesses. Geographically, the company derives maximum Lease rent revenue from the United States, followed by Europe, Asia-Pacific (excluding India), India, South America, Canada, Central America, and the Middle East.

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Share on Social Networks: